Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DO YOU HAVE PROOF OF WHAT YOUR SAYING????
COME UP WITH EVIDENCE FOR THE WHOLE IHUB VIEWING WORLD THAT YOU KNOW BY YOUR ON THE RECORD STATEMENT LAID OUT BELOW THAT THEY WERE 3 CTIX SHAREHOLDERS: Reference Post #179632 BY SCOTTSMITH
PROVE IT SCOTT - YOU MADE THE STATEMENT
GIMME A BREAK AGAIN!!
THEY BROUGHT DR BERTOLINO IN TO BE BLINDFOLDED EVERY DAY AND WIRED UP AS PAVLOV'S DOG??????????
DO SOME READING WHY THIS MAN WAS BROUGHT IN FROM HIS BACKGROUND.
http://finance.yahoo.com/news/cellceutix-corporation-announces-industry-veteran-170000534.html
http://www.fiercepharma.com/sales-and-marketing/novartis-puts-cosentyx-on-track-for-4b-plus-new-psoriatic-arthritis-data
HE KNOWS THE VALUE OF THE CTIX DRUGS AND THE NEGOTIATIONS INVOLVED TO FINALIZE.
The bottom line is Dr Bertolino is running the activities for partnership engagements.
You can slander/defame Leo on this board, but I've been on this board now for several years and have an idea of the games played here to push things down and attempt to ride it back up.
For those playing these games, don't think your collaborations are free from possible suspect activities. It may catch up with you.
Cellceutix and Ashcroft law firm are probably not finished with their work.
I would like to call you out and cite many examples of the words you have listed here:
spin
omission
mis-direction
less than truthful statement
outright falsehood
Your adjectives mean nothing to me!!
Please so provide valid answers with support over the last three years
concerning your adjectives you put out for all of IHUB to see.
And provide a general, scientific and honest discussion about the results and progress of each drug for each indication that is currently on trial.
By the way, should you decide to volunteer on this project, fair enough you can take until June 8.
It would not suprise me if its eventually found out you and some others are part of a big interconnected scheme. It amazing you come around when the stock is falling after some previous rise and spew your stuff. And your adamantly trying to keep it below $1.
It's easy for you to put out those % numbers and make yourself look good after 2 days of trading.
Never any acknowledgment of 5 clinical trials for 3 seperate drugs without a failure. And very good results.
Being exposed really far fetched, they have given you 2 interim analysis data sets from Mar 21 and Mar 27 and your not satisfied??
http://www.cellceutix.com/press-release/2017/4/3/cellceutix-reports-very-encouraging-interim-analysis-of-phase-2-drug-candidate-brilacidin-for-severe-oral-mucositis-om-in-head-and-neck-cancer-patients-high-potential-for-preventative-treatment
http://www.cellceutix.com/press-release/2017/3/19/cellceutix-releases-favorable-topline-findings-as-part-of-interim-analysis-of-phase-2-drug-candidate-brilacidin-for-the-treatment-of-inflammatory-bowel-disease
Are these recent enough for you?
What more can they give you without waiting on trial results??
I beg to differ on these conjectures that something happened. Everyone should know darn well this was not a conference call to entertain shareholder/investor questions and provide answers.
How were they going to give you more details about the call early in the week(this week), have you submit your questions in 2 days time, and have solid or timely answers for you by mid Wednesday??
This conference call was probably started Tues/Wed and finalized sometime Wednesday.
It wasn't meant to be a question/answer participatory setting.
Gimme a break about this happened and that happened (hand over mouth).
You have until June 1 to come up with things to ask and obtain answers.
Sounds generous enough to me.
https://en.wikipedia.org/wiki/Conference_call
A conference call is a telephone call in which someone talks to several people at the same time. The conference calls may be designed to allow the called party to participate during the call, or the call may be set up so that the called party merely listens into the call and cannot speak. It is sometimes called ATC (audio tele-conference).
It doesn't matter - they said the CC was set for later in the week as they stated previously, and they met their obligation.
If it's Prurisol interim data, BP may have priority over us in viewing and discussing the results with ctix in meetings of whatever form.
If there is multiple party interest, then it takes time.
I'm hoping Brilacidin UP data for cohort C is also presented.
So BP can have data from both platforms (P and B) to chew on simultaneously.
If there is new trial data to present, then he would want to coordinate the data reception to fit in with the conference call. Giving a heads up about any new data results that would be part of the conference call, may give more eyes to the conference call.
I don't really know if this is the case in this situation....
Thanks very much for your insight.
Seems like you've had a majority lead development in the brilacidin and kevetrin platforms and know how they're progressing.
Your such a truthseeker. Godspeed.
I don't know if your researched company had too much debt. That will certainly get you in trouble. This is clearly not the case with ctix.
Any success with Prurisol 2B (near equivalency, equivalency, or superiority to Otezla) will get ctix the cash they need to push Brilacidin oral mucositis, Brilacidin ulcerative colitis, Brilacidin ABSSSI thru Phase 3 completions and Kevetrin for Ovarian Cancer thru Phase 2 completion on their own. And should the current interim analysis of these Brilacidin drugs be confirmed after Phase 2Bs, ctix becomes a highly sought-out buyout candidate.
RunningGirl,
The interim analysis for Prurisol could come at anytime now.
Possibly even a two-stage interim analysis (like BOM is doing).
a) Preliminary interim analysis
followed by an
b) Interim analysis
Example below is an interim analysis for a psoriasis trial at patient 103 of 300 patients.
A psoriasis trial interim analysis that occurred at less than the 1/2 way point
http://www.prnewswire.com/news-releases/interim-analysis-supports-continuation-of-can-fites-phase-23-psoriasis-clinical-study-with-cf101-173296061.html
Maybe they will bring a few of the Brilacidin founders on board.
Yep, I hope your right and for the good of the population out there needing new safe and effective drugs. As well for the investors here who have been long 2-5 years and having the patience to stay the course.
One would think if the Prurisol Phase 2B results are equal or superior to otezla, then ctix has leverage to complete a fair deal by combining both B and P as one complete package deal to a BP.
Yep, very well done. Have a great day!
Cool...looks tested out ok.
Please note Grade > 3 in your repost of 3/27/2016 PR should be Grade >= 3
George,
Phase 2 interim analysis of Brilacidin OM is probably
now within 1-3 weeks.
George, IGA 0/1 is >= PASI 90 I believe. Correct me anyone if I've misinterpreted...
PASI 90 is better than PASI 75 for skin clearance.
I wanted to verify you were right. The popup did show up three times for me with it saying Cramer having ctix in his portfolio. Later, I was not seeing it.
You were definitely right about what you saw.
See my post #175734
I did this at one time, but capturing the cellceutix text along with the wording in the popup "Jim Cramer currently owns this stock in his portfolio" - couldn't read the popup text as it was too small in my profile image.
I don't think I can insert a png file in here.
Seems to be no upload button.
I have a screenshot, don't know how to place it here
Anyone know how to insert a png file in here???
Yes, the popup overlaying ctix information says he owns the stock in the portfolio.
But I only saw this the first time I clicked the https portion of the link.
The popup is not coming up a second time when I click the link.
Most recent update on healthcare costs due to oral muscositis. Adds 18k per treatment to cancer costs.
Reference:
http://www.soligenix.com/pipeline/biotherapeutics/sgx942-oral-mucositis/
About Oral Mucositis
Mucositis is the clinical term for damage done to the mucosa by anticancer therapies. It can occur in any mucosal region, but is most commonly associated with the mouth, followed by the small intestine. Mucositis affects approximately 500,000 people in the US per year and occurs in 40% of patients receiving chemotherapy. Mucositis almost always occurs in patients with head and neck cancer treated with radiation therapy (>80% incidence of severe mucositis) and is common (40-100% incidence) in patients undergoing high dose chemotherapy and hematopoietic cell transplantation, where the incidence and severity of mucositis depends greatly on the nature of the conditioning regimen used for myeloablation. Mucositis can be severely debilitating and can lead to infection, sepsis, the need for parenteral nutrition and narcotic analgesia. The gastro-intestinal damage causes severe diarrhea. These symptoms can limit the doses and duration of cancer treatment, leading to sub-optimal treatment outcomes. Direct and indirect consequences of mucositis have been estimated to add ˜$18K per patient to cancer treatment costs.
The big take from cellceutix is that insurance companies and medicare would most likely reimburse this treatment. It's a debilitating side effect of cancer treatment that would cost based on ....
Here's a quote from March 2007, 10 years earlier.
Oral mucositis was associated with an incremental cost of $1700-$6000, depending on the grade. CONCLUSIONS: Head-and-neck RT causes OM in virtually all patients. Oral mucositis is associated with severe pain, significant weight loss, increased resource use, and excess cost. Preventive strategies are needed.Mar 29, 2007
A first-time oral for psoriasis (Otezla) captured a 20% share in 3 years.
A first-time, highly-effective 3xdaily spit and swish mouthwash will capture what ? market share in 3 years from approval?
Let's say 20% in 3 years on the market.
20% of 400,000 is 80,000 patients times $3000 treatment with full revs of $240 million sounds like reasonable achievement. Word and marketing will get around as 20% will be projected to 40-50% with $480-$600 million revs (at this point would there be any close competitors) and at what amount would peak sales hit?
I'm sure there are biotechs on the Nasdaq today that are capturing $240 million in annual revs and have a market cap of 1-2 billion. BOM is just one of the 3 indications for Brilacidin now in at least phase 2 clinical trials. (2 in phase 2, 1 approved for phase 3)
I sure hope this possible answer (BOM) to limitless cancer suffering succeeds even if my projections here are too high.
That $6 million cost was given with an estimate of 30 sites.
Cellceutix is running 25 sites to complete the trial.
I have looked at Celgene's Otezla's phase 3 of 844 patients with 76 sites and compared it's completion time with Prurisol's phase 2B with 25 sites and 189 patients. Looks like Otezla Phase 3 maybe did 11.78 patients per week and probably 15 months to complete.
To do this rate patients per week rate with 189 patients (like Cellceutix has for 2B) would take about 17 sites. Cellceutix has 25 sites running with their Prurisol 2B.
The Prurisol 2B trial should be finished enrolling no later than March 31.
In other words, anytime now. IMHO
We are encroaching on week 18, about 4 1/2 months. Nothing is perfect in my estimate to grant this true, as all factors were not considered. However, the # of exclusion criteria are just about the same for Celgene Otezla trial and Cellceutix Prurisol 2B and Cellceutix is using 7 more sites to recruit what would take doing 189 patients (17 sites) for the Otezla Phase 3.
One holdup with recruiting may have come during Thanksgiving week and the Christmas holiday weeks (Dec 22 - Jan 2).
It's whenever as in it will happen soon.
Why? Its open label trial your an investor either long, short,
or both or looking in thinking whether to invest here.
Would like to see the progression reports for each dose cohort completion.
Rather not wait 10-11 months for everything (started June 15 last year).
It gives direction where they may be headed for future indications of Brilacidin and how much more I may want to invest.
Ehrlich on Feb 16, said in approximately 2 weeks for the BUP interim analysis.
The March 3 PR indicates the CRO is compiling the data.
The wait can't be that much longer.
http://www.cellceutix.com/press-release/2017/2/15/y3616250ilexnq8enkoy8lelciljue
Brilacidin—Inflammatory Bowel Diseases Ulcerative Proctitis/Proctosigmoiditis (Phase 2a Trial)
o This Proof-of-Concept trial includes enrolling 18 patients divided evenly into three cohorts. Review of safety data from the first 6 patients revealed that Brilacidin, administered for 6 weeks as a retention enema, at 50 mg once daily, appeared well-tolerated, with no measurable systemic absorption detected. Clinically meaningful improvements in symptoms were also demonstrated, as measured by physician assessments and patient reported outcomes, further supported with endoscopic evaluation. Brilacidin may show greater efficacy at higher dosing levels in the trial, which are comprised of 100 mg for the current cohort and 200 mg for the third cohort. Cellceutix believes that a successful trial creates an opportunity to explore Brilacidin for an array of other hard-to-treat Inflammatory Bowel Diseases that currently lack effective therapeutics.
o Upcoming Milestone: Cellceutix projects that an interim analysis of the second cohort will be completed in approximately two weeks. The trial is anticipated to be completed in 2Q2017.
Brilacidin OM interim analysis is 6-8 weeks from Feb 16, 2017:
February 16, 2017
Cellceutix Reports on Q2 Fiscal 2017, Prepares for Important Clinical Milestones
Corporate
BEVERLY, MA – February 16, 2017 (GLOBE NEWSWIRE) Cellceutix Corporation, (OTCQB: CTIX) (“the Company”),
Brilacidin—Oral Mucositis (Phase 2 Trial)
o Enrolling 60 patients, the study is evaluating Brilacidin as an oral rinse, 3 times daily for 7 weeks, to prevent and control Oral Mucositis (OM) in patients receiving chemoradiation therapy for head and neck cancer. Even though over 400,000 patients in the U.S. suffer from this condition, presently there are no approved drugs for the treatment of OM in this population, with only limited palliative care options available. Cellceutix’s goal with this trial is to show that Brilacidin has dual functionality in not only shortening the duration and intensity of OM in patients with head and neck cancers, but also preventing the onset of the condition, an accomplishment no other pharmaceutical company has achieved.
o Upcoming Milestone: Interim analysis of the Phase 2 trial is expected in approximately 6 to 8 weeks.
PR Reference for release of Brilacidin OM interim ananlysis:
http://www.cellceutix.com/press-release/2017/2/15/y3616250ilexnq8enkoy8lelciljue
Maybe if the cohorts A,B,C are impressive enough, they can run a
Phase 2B/3 like this example with collaboration partner Gilead
example of phase 2B/3 for ulcerative colitis
Your willing to make a clear cut figure of that amount with 9 months left in the year and a minimum 3 trial results phase 2 being out this year??
And your clear cut on partnership at Q4 the earliest??
You know things we don't know, it seems so, with such definite tone of speech.
But you don't work for cellceutix...and aren't in on any partner discussions or budget plans...just an outsider...throwing things up in the air.
You've really been on top of things.
Thanks for the update romaa
Correct Karin.
Below is an interim analysis for a psoriasis trial at patient 103 of 300 patients.
a psoriasis trial interim analysis at less than the 1/2 way point
You may have somewhat an answer based on financiers, but the first part...millions of shares usually free...makes no sense